WENDY KEITEL to Antibodies, Viral
This is a "connection" page, showing publications WENDY KEITEL has written about Antibodies, Viral.
Connection Strength
3.665
-
Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis. Vaccine. 2019 09 03; 37(37):5535-5543.
Score: 0.417
-
Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women. Vaccine. 2018 12 18; 36(52):8054-8061.
Score: 0.402
-
Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons =18 Years Old. J Infect Dis. 2015 Aug 15; 212(4):552-61.
Score: 0.309
-
Increasing doses of an inactivated influenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants. J Infect Dis. 2008 Oct 01; 198(7):1016-8.
Score: 0.199
-
Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med. 2006 May 22; 166(10):1121-7.
Score: 0.169
-
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clin Infect Dis. 2024 06 14; 78(6):1757-1768.
Score: 0.148
-
Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial. Vaccine. 2023 04 17; 41(16):2716-2722.
Score: 0.136
-
Topical Imiquimod Does Not Provide an Adjuvant Effect When Administered With Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults. J Infect Dis. 2021 11 22; 224(10):1712-1719.
Score: 0.124
-
Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults. J Infect Dis. 2001 Jan 15; 183(2):329-332.
Score: 0.116
-
Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants. Vaccine. 2020 07 14; 38(33):5355-5363.
Score: 0.112
-
An evaluation of cytokine and cellular immune responses to heterologous prime-boost vaccination with influenza A/H7N7-A/H7N9 inactivated vaccine. Hum Vaccin Immunother. 2020 12 01; 16(12):3138-3145.
Score: 0.111
-
Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents. Vaccine. 2019 08 23; 37(36):5161-5170.
Score: 0.106
-
Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clin Diagn Lab Immunol. 1996 Sep; 3(5):507-10.
Score: 0.086
-
Challenges Remain for Influenza Vaccination of Children. J Infect Dis. 2016 11 15; 214(10):1470-1472.
Score: 0.086
-
Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant. Clin Vaccine Immunol. 2016 01; 23(1):73-7.
Score: 0.082
-
Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-na?ve subjects. Vaccine. 2015 Sep 22; 33(39):5225-34.
Score: 0.080
-
High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol. 1994 Oct; 32(10):2468-73.
Score: 0.076
-
Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. J Infect Dis. 1993 Feb; 167(2):305-11.
Score: 0.067
-
Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine. 1993; 11(9):909-13.
Score: 0.067
-
Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis. 2012 Oct 01; 206(7):1069-77.
Score: 0.065
-
A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine. 2010 Apr 09; 28(17):3025-9.
Score: 0.054
-
Antibody quantity versus quality after influenza vaccination. Vaccine. 2009 Oct 23; 27(45):6358-62.
Score: 0.054
-
Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine. 2010 Jan 08; 28(3):840-8.
Score: 0.054
-
Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans. Vaccine. 2009 Aug 27; 27(39):5344-8.
Score: 0.053
-
Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine. 2009 Nov 05; 27(47):6642-8.
Score: 0.052
-
Increased antibodies against unfolded viral antigens in the elderly after influenza vaccination. Influenza Other Respir Viruses. 2007 Jul; 1(4):147-56.
Score: 0.046
-
A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy Adults. J Infect Dis. 2023 08 11; 228(3):287-298.
Score: 0.035
-
Repeated immunization of children with inactivated and live attenuated influenza virus vaccines: safety, immunogenicity, and protective efficacy. Semin Pediatr Infect Dis. 2002 Apr; 13(2):112-9.
Score: 0.032
-
Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. Vaccine. 2019 05 01; 37(19):2561-2568.
Score: 0.026
-
Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine. 1997 Jul; 15(10):1114-22.
Score: 0.023
-
Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. Vaccine. 2017 03 23; 35(13):1675-1682.
Score: 0.022
-
Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies. Vaccine. 2016 07 19; 34(33):3796-802.
Score: 0.021
-
Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015 Jul 21; 314(3):237-46.
Score: 0.020
-
Comparison of trivalent cold-adapted recombinant (CR) influenza virus vaccine with monovalent CR vaccines in healthy unselected adults. J Infect Dis. 1995 Jul; 172(1):253-7.
Score: 0.020
-
Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine. J Infect Dis. 2015 Aug 15; 212(4):525-30.
Score: 0.019
-
Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine. 2015 Jan 01; 33(1):163-73.
Score: 0.019
-
Prenatal passive transfer of maternal immunity in Asian elephants (Elephas maximus). Vet Immunol Immunopathol. 2013 Jun 15; 153(3-4):308-11.
Score: 0.017
-
Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. J Infect Dis. 2011 Sep 15; 204(6):854-63.
Score: 0.015
-
Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. Vaccine. 2011 Oct 19; 29(45):8066-72.
Score: 0.015
-
Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine. 2011 Oct 06; 29(43):7357-63.
Score: 0.015
-
Cold recombinant influenza B/Texas/1/84 vaccine virus (CRB 87): attenuation, immunogenicity, and efficacy against homotypic challenge. J Infect Dis. 1990 Jan; 161(1):22-6.
Score: 0.014
-
Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine. 2009 Aug 13; 27(37):5091-5.
Score: 0.013
-
Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med. 2008 Dec 08; 168(22):2405-14.
Score: 0.013
-
Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. Am J Epidemiol. 1988 Feb; 127(2):353-64.
Score: 0.012
-
A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine. 2007 Jul 20; 25(29):5367-73.
Score: 0.011
-
Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. Vaccine. 2005 Feb 03; 23(11):1414-25.
Score: 0.010
-
Acquisition of serum antibodies to specific viral glycoproteins of parainfluenza virus 3 in children. J Virol. 1984 Dec; 52(3):828-32.
Score: 0.010
-
Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine. 2002 Jan 15; 20(7-8):1099-105.
Score: 0.008
-
Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren. J Infect Dis. 1996 Feb; 173(2):453-6.
Score: 0.005